poisar

Stocks · News reference

Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Benzinga Newsdesk

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

URGN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 19 new employees, with up to 117,100 ordinary shares issuable upon vesting over three years. The company also announced a strategic collaboration and investment agreement with IntraGel Therapeutics to access a biodegradable sustained-release gel platform and expand its uro-oncology and specialty cancer pipeline.

    URGN